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Abstract
Background: Despite large-scale efforts to diagnose people living with HIV, 54% remain undiagnosed in sub-
Saharan Africa. The gap in knowledge of HIV status and uptake of follow-on services remains wide with much lower
rates of HIV testing among men compared to women. Here, we design a study to investigate the effect on uptake
of HIV testing and linkage into care or prevention of partner-delivered HIV self-testing alone or with an additional
intervention among male partners of pregnant women.
Methods: A phase II, adaptive, multi-arm, multi-stage cluster randomised trial, randomising antenatal clinic (ANC)
days to six different trial arms. Pregnant women accessing ANC in urban Malawi for the first time will be recruited
into either the standard of care (SOC) arm (invitation letter to the male partner offering HIV testing) or one of five
intervention arms offering oral HIV self-test kits. Three of the five intervention arms will additionally offer the male
partner a financial incentive (fixed or lottery amount) conditional on linkage after self-testing with one arm testing
phone call reminders.
Assuming that 25% of male partners link to care or prevention in the SOC arm, six clinic days, with a harmonic
mean of 21 eligible participants, per arm will provide 80% power to detect a 0.15 absolute difference in the primary
outcome. Cluster proportions will be analysed by a cluster summaries approach with adjustment for clustering and
multiplicity.
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Discussion: This trial applies adaptive methods which are novel and efficient designs. The methodology and
lessons learned here will be important as proof of concept of how to design and conduct similar studies in the
future. Although small, this trial will potentially present good evidence on the type of effective interventions for
improving linkage into ART or prevention. The trial results will also have important policy implications on how to
implement HIVST targeting male partners of pregnant women who are accessing ANC for the first time while
paying particular attention to safety concerns. Contamination may occur if women in the intervention arms share
their self-test kits with women in the SOC arm.
Trial registration: ISRCTN, ID: 18421340. Registered on 31 March 2016.
Keywords: Adaptive trials, HIV self-testing, Cluster randomised trials, HIV, Multi-arm multi-stage
Background
Sub-Saharan Africa (SSA) accounts for 70% of the global
HIV burden despite rapid scale up of HIV services in-
cluding testing [1]. Analysis of the HIV care cascade in-
dicates a striking fall-off in numbers between testing and
linkage into HIV care or prevention [2]. Men regularly
feature among populations with lower uptake of HIV
testing across SSA [3] and lower rates of linkage into
care or prevention [4] in the era of extremely ambitious
targets for HIV [5]. The 90-90-90 targets aim to diag-
nose 90% of all HIV cases, start 90% of diagnosed HIV
cases on treatment, and achieve viral suppression in 90%
of those started on HIV treatment [5]. Awareness of
HIV status among male partners of antenatal clinic
(ANC) women attendees is low with less than 35%
undergoing HIV testing when invited through their part-
ner [6]. African women face substantial risk of acquiring
HIV infection, estimated at 3.6% per pregnancy in study
cohorts [7]. Over 90% of pregnant women access ANC
services, providing an ideal opportunity to reach both
partners with HIV testing and counselling services
(HTS) [8].
A number of strategies have been found to increase
uptake of HIV testing among male partners of ANC at-
tendees, including home-based testing [9, 10], provider-
initiated testing and counselling (PITC) [11], couples
testing during antenatal visits [12] and home-based
couple or partner testing [13, 14]. Key limitations of
these strategies include: logistical difficulties of wide-
scale implementation where home visits are required,
lack of convenience, costs, lack of confidentiality and
failure to prioritise men’s own health [15–17]. HIV self-
testing (HIVST) is an alternative approach with the po-
tential to increase couple or partner testing [18] and has
been found to be highly acceptable to men in Malawi
[19, 20]. Here, we define HIVST-plus as offering HIV
self-testing along with an additional intervention aimed
at improving linkage into HIV care or prevention. Such
additional interventions include facilitated linkage [21],
financial incentives (FI) [22] and short messaging
services (SMS) [23].
This wide range of interventions presents technical
challenges related to appropriate study design and ana-
lysis methods in order to identify optimal strategies [24].
Such complexity can be handled by applying multi-arm,
multi-stage (MAMS) designs, which are more flexible by
allowing pre-specified adaptations at interim analysis, as
well as more efficient with respect to time and cost than
standard parallel designs [25, 26]. In MAMS designs,
several interventions are included in the first stage of
the trial with pre-specified adaptations at interim ana-
lysis. Such a trial may either be a multi-stage phase II or
III trial, or can be done as a seamless trial combining all
the three trial phases separated by interim analyses [27].
In general, MAMS designs involve comparing each of
several interventions to a control arm using interim ana-
lysis [25], providing an unbiased approach to investigat-
ing and selecting multiple phase II candidates under
consideration for a future phase III trial [26]. Although
predominantly used in the pharmaceutical industry to
date, MAMS trial designs could have value in public
health evaluations where randomising at the cluster level
is often preferred. Furthermore, public health interven-
tions are often complex involving multiple components
and understanding the effect of each component may
help inform the optimal choice [28].
Here, we describe the design of a phase II, adaptive,
MAMS cluster randomised trial (CRT) with clinic day
(not individual women) as the unit of randomisation.
Our primary objective is to identify leading candidate in-
terventions based on HIVST for improving HIV testing
and linkage into care or prevention for male partners of
ANC attendees in Blantyre, Malawi.
Methods
Design
This is a phase II, adaptive, MAMS CRT using ANC day
as the unit of randomisation. As a phase II trial the
study is intended to investigate efficacy relating to up-
take of testing and subsequent HIV services by the male
partner, safety outcomes, and to provide an estimate of
acceptability to the pregnant woman. The trial will have
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one interim analysis during which pre-planned adapta-
tions will be made as described below, followed by final
analysis at the end of the second stage (two-stage
MAMS design). The first stage will have six arms with
one SOC and five intervention arms (Fig. 1). At the end
of the first stage, a 3-point criteria will be considered by
an independent Data Safety and Monitoring Board in
order to drop intervention arms. Each intervention ver-
sus the SOC yielding p > 0.2 will be considered to be
dropped; safety concerns; and costs will guide recom-
mendations to drop or retain an intervention arm at the
end of the first stage. The trial will not stop for efficacy
at the interim analysis.
Analysis of second stage (end of trial) data will poten-
tially lead to a definitive study (phase III) involving arms
that show promise at the end of the second stage. A
sample size of 36 ANC days (six per arm) will be re-
quired for the first stage (see the ‘Sample size consider-
ations’ section below for justification). In order to
control the family wise error rate (FWER) at the speci-
fied significance level (α = 0.2) for the five comparisons
with the SOC arm, Dunnett’s test [29] will be applied.
Trial simulation
A simulation study was set up to compute the overall
probability of the trial to find at least one intervention
whose efficacy is different compared to the SOC arm at
the end of stage 2 (minimal power). The simulation was
conducted under the alternative hypothesis with an as-
sumed effect of 29–40% versus 25% in the SOC arm
(Table 1). Additional key assumptions included that each
ANC day (cluster) would have 20 participants with
power set at 80% for each stage (Table 1). The simula-
tion showed that at least two interventions would signifi-
cantly improve the trial primary outcome (Table 2).
These interventions would then be further tested in a
potential phase III trial.
Study setting and population
The study will recruit participants fromNdirande, Zingwangwa
and Bangwe primary health centres (PHC) in urban
Blantyre, Malawi. All women attending for antenatal
care for the first time at these PHCs and their male
partners will be eligible for participation (see Additional
file 1). Women and their male partners will be excluded
if they received couple or partner HIV testing in the
current pregnancy; if either are aged below 18 years of
age; if the male partner is reported to be HIV positive
by the pregnant woman; if already recruited in this trial;
and if not urban Blantyre resident. Malawi has recently
(September 2016) implemented the test and treat ap-
proach where everyone diagnosed with HIV starts anti-
retroviral treatment (ART) immediately.
Randomisation and recruitment flow
Each ANC day was randomised to any one of the six
trial arms using a randomised permuted block design in
a ratio of 1:1:1:1:1:1 (Fig. 2). All three PHCs are of com-
parable size and serving comparable catchment popula-
tions, and, therefore, stratification was not deemed
necessary. The allocation sequence was generated by an
independent statistician using computer-generated ran-
dom numbers [30]. The file containing the complete
randomisation sequence will only be accessible to the in-
dependent statistician.
Field workers will enrol women into one of the six
study arms on the morning of each ANC day after
receiving the randomisation allocation for that ANC day
(see Additional file 1). Women will receive study infor-
mation in a group while in the ANC waiting area
followed by one-on-one eligibility assessment and subse-
quent recruitment. Study information given during
group sessions will not reveal details of arm-specific pro-
cedures to avoid potential non-participation associated
with knowledge of procedures for each arm. All women
who show interest at this stage will provide unwritten
consent to participate by show of hands followed by
written or witnessed thumb-print consent.
Standard of care arm (SOC)
In the SOC arm women will receive a personalised letter
only addressed to their male partner inviting him to go
to the male-friendly clinic (MFC) to have an HIV test,
receive HIV care or prevention and pregnancy-related
education. The MFC is being implemented by the trial,
and will offer men attending confirmatory HIV testing,
facilitate linkage to HIV care or voluntary male medical
circumcision (VMMC), and pregnancy-related health
education.
Fig. 1 Schema of the phase II, adaptive, multi-arm, multi-stage cluster
randomised trial. A two-stage, multi-arm, multi-stage (MAMS) trial
design starting with six arms in the first stage. At interim analysis (end
of first stage) some trial arms may be dropped, with recruitment to the
remaining arms aiming to narrow down to a few arms that may be
carried forward to a definitive (phase III) trial
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Intervention arms
In all five intervention arms, the woman will receive
self-test instructions and two self-test kits to take home.
The test kits, test instructions and a personalised letter
will be delivered to the male partner by the woman in
order to initiate dialogue for him to test and link to the
MFC for HIV care or prevention as appropriate.
The five intervention arms differ with respect to finan-
cial incentives, participation in a lottery, and phone call
reminders received by the male partner. Women in the
first intervention arm will only receive the letter and the
two self-test kits. In the two fixed financial incentive (FI)
arms, male partners who self-test (test) and link into the
MFC will receive an equivalent of US$3 or US$10 in the
low- and high-FI arms, respectively. In the lottery FI
arm, male partners who test and link into the MFC will
have a 10% chance of winning US$30. In the final inter-
vention arm, male partners will receive a phone call,
through a number given to the study team by the
woman at enrolment, to remind him to test and link
into the MFC. All FIs will be disbursed as cash through
mobile money in the trial in order to safeguard the
safety of staff and are conditional on the male partner
linking into the MFC.
Primary and secondary outcomes
The primary outcome is the proportion of male partners
of ANC attendees who test for HIV and link into HIV
care or prevention within 28 days of enrolling the
woman (Fig. 3). Thus, the primary outcome is defined as
presentation of the male partner at the MFC with a used
self-test kit (if in the intervention arm) or undergoing
spot HIV testing with a study HIV counsellor within
28 days AND being referred for HIV care if HIV positive
or VMMC if HIV negative and uncircumcised. There
are four secondary outcomes: the proportion of male
partners who test for HIV within 28 days (as reported by
the woman); the proportion of women who accept to
participate in their allocated trial arm; risk of serious ad-
verse events (SAEs) in men and women in the study;
and the total cost of implementing each trial arm. All
outcomes will be analysed at cluster level (see the ‘Statis-
tical analysis’ section).
Outcome measurement
All male partners who present at the MFC in the SOC
arm will be offered a single finger-prick HIV test with
Determine 1/2™ as per Malawi national testing algo-
rithm. An HTS counsellor will re-read a used self-test
kit if the participant returns one as evidence of self-
testing in the intervention arms. Participants who return
with unused self-test kits or without self-test kits will be
requested to self-test in the presence of the counsellor.
All HIV results will be recorded on a data form followed
by confirmation of HIV-positive results in parallel using
Determine 1/2™ and Uni-Gold, with facilitated linkage to
HIV care. All men who test HIV negative and report to
be uncircumcised will be offered VMMC to be con-
ducted by Population Services Internal (PSI). Thus,
measurement of primary outcome includes evidence of
an HIV test, confirmatory testing, and referral to HIV
care or VMMC as appropriate within 28 days of the
woman being recruited.
The secondary outcome of HIV testing among male
partners will also be measured though proxy reporting
by the woman using audio computer-assisted self-
interview (ACASI) during her next ANC visit 4 weeks
later. Participation in the allocated trial arm will be mea-
sured by computing the proportion of women who
accept to participate after receiving trial-arm-specific in-
formation using the denominator of the total number of
women who are eligible. All women will be asked to re-
port any adverse events through ACASI at their next
Table 1 Simulation inputs
Description Input
Number of ANC days (clusters) per arm for both stages 6–20
Number of participants per ANC day 20
Linkage to care or prevention for the SOC arm in stages
1 and 2
25%
Linkage to care or prevention for the 5 intervention arms
in stages 1 and 2
29–40%
SD of the mean of cluster-level proportions per arm
(7 clusters, stage 1)a
0.05–0.08
ANC antenatal care, SOC standard of care, SD standard deviation
aComputed using σ = k × μ where σ is the standard deviation of the true
cluster-level proportions; k is the coefficient of variation (assumed to be 0.2)
and μ is the mean of the proportions per arm
Operating characteristics: stage 1 α = 0.2; stage 2 α = 0.1; 1 − β = 0.8
Table 2 Simulation results
First stage Simulations
in which
arm was
dropped at
interimc
Assumed
Study arm aProportion SDb Proportion Proportiond
1 Standard of care 0.250 0.048 NA 0.250
2 Intervention 0.291 0.055 0.441 0.290
3 Intervention 0.299 0.058 0.336 0.300
4 Intervention 0.310 0.059 0.215 0.310
5 Intervention 0.321 0.061 0.114 0.320
6 Intervention 0.400 0.078 0.000 0.400
Exact intervention not specified here as there is no evidence about a particular
one of the 5 interventions being investigated
SD standard deviation
aProportion of male partners linked to care or prevention
bAssumed (0.050, 0.058, 0.060, 0.062, 0.064, 0.080) in arms 1–6, respectively
cScenarios assumed for the 6 trial arms at the start
dIf p value was > 0.2 at interim analysis, discontinued from recruitment
Choko et al. Trials  (2017) 18:349 Page 4 of 10
ANC visit while men who present to the MFC will be
asked to report any adverse events. A costing tool vali-
dated in urban Blantyre [31] will be used to capture the
costs associated with providing the service in each trial
arm. The cost and outcome data will be used to estimate
the cost per male partner tested for HIV, and cost per
HIV-positive male identified through all SOC and inter-
vention arms.
Sample size considerations
A modification of the formula for sample size calculation
for a MAMS design for binary outcomes [32] was made
based on the methodology for CRTs [33] to identify each
stage of the trial. We assume that each ANC day will
have at least 40 women attending for the first time, 90%
will satisfy the eligibility criteria and at least 60% will
consent to participate, so having a cluster size of at least
21. We also assume that in the SOC arm 25% of men
will satisfy the definition of the primary outcome [34].
For the first stage, six ANC days per arm (36 days in
total) would be needed to detect an absolute difference
of 15% in linkage compared to 25% in the SOC arm
using a FWER of 0.2 with 80% pair-wise power and a co-
efficient of variation (k) of 0.10 [21]. In general, under
the stated assumptions the trial has 80% chance of de-
tecting a 1.6-fold increase in testing and linkage within
28 days compared to SOC at 5% significance level. Sam-
ple size for the second stage will be re-calculated based
on empirical estimates at interim analysis with FWER of
0.1 and 80% power.
Very little clustering within ANC days is expected,
hence we have assumed that k = 0.10 (intraclass correl-
ation coefficient = 0.003). The simulation study assumed
that k = 0.2 and differs with the final design in this re-
spect resulting in six and seven clusters per arm in the
final design and the simulation, respectively. A larger
than conventional (0.05) FWER of 0.2 and 0.1 for stage
1 and stage 2, respectively, may lead to erroneously tak-
ing forward an ineffective intervention. However, given
that this is a phase II trial this is not a major concern as
Fig. 2 Randomisation, recruitment, and outcome evaluation. Each cluster (antenatal clinic day) is randomised to any of the six trial arms. All
women attending their first antenatal clinic are briefed about the general purpose of the trial without receiving trial arm-specific information.
Women then undergo one-on-one eligibility screen and arm-specific information. Women who are eligible and accept to participate are then
given a male partner invitation letter alone or with two self-test kits to take home
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it guards against dropping interventions that may other-
wise prove to be effective in a larger, phase III trial. A
more conventional pair-wise power of 0.8 was chosen to
ensure that there is a high chance of taking forward
most of the efficacious interventions from stage 1.
Statistical analysis
Analyses will be done in R [35] and Stata 14.0 (Stata
Corp., TX, USA). Baseline characteristics will be com-
puted as proportions or median (interquartile range
(IQR)), as appropriate, by arm in each of the two stages
of the trial. Any variables that show imbalances will be
adjusted [33] for when analysing the trial outcomes at
the end of the second stage. We will assume that the
two stages of the trial are independent [26] and will
proceed to carry out a test of the null hypothesis of no
difference in effectiveness of each intervention compared
to the SOC. We will do this by analysing data from the
first stage first followed by interim decisions to drop
arms; then we will conduct and analyse data from the
second stage (no overlap of participants from the first
stage). Analysis of the whole trial will then be based on
combined p values from both the first stage and the
second stage using the weighted inverse normal (WIN)
method [36] for arms that are not dropped at interim. A
weighted average of the log (risk ratio (RR)) will be com-
puted for the whole trial using estimates from each trial
stage. All analyses will be by intention-to-treat taking as
the denominator the number of women who were
eligible and take into account the clustered design.
Given the small number (six) of clusters per arm in
the first stage, analysis will be by cluster-level summaries
using mean of proportion of male partners per clinic day
who link to care or prevention in each arm [33]. The
STUDY PERIOD
Pre 
Enrolment
Enrol
ment Allocation Post-allocation Close-out
TIMEPOINT -t1 Week 0 Week 0 W1 W2 W3 W4 W32
RANDOMISATION 
AND ALLOCATION X
ENROLMENT:
Group education X
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
Invitation letter 
only
Invitation letter  2 
ST kits
Invitation letter  2 
ST  $3
Invitation letter  2 
ST  $10
Invitation letter 2 
ST  lottery
Invitation letter  2 
ST  reminder
ASSESSMENTS:
Demographics, HIV 
testing history
X X
Had an HIV test; 
linked to clinic
X X X
Had adverse event; 
cost per person 
tested and linked
X X X X X
Fig. 3 Schedule of enrolment, interventions and assessments (Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT))
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proportion of male partners who link into care or pre-
vention will be computed per clinic day for each arm
with number of men achieving the primary outcome and
the number of women eligible and recruited in ANC on
enrolment day as denominator. A log transformation of
the clinic day proportions will be applied if a positive
skew is observed [33]. The geometric mean of clinic day
proportions in each of the five intervention arms will be
compared to the SOC arm using an unpaired t test [33].
An estimate of the RR and a 95% CI will also be com-
puted for each comparison by dividing the geometric
mean of proportions in each intervention arm and the
geometric mean of proportions in the SOC arm [33].
This analysis involves more than two comparisons
with a single control arm which can lead to higher than
the specified FWER or significance level. Therefore,
Dunnett’s test [29] will be applied to the t-statistics gen-
erated from the unpaired t test to control the stage-wise
FWER. Final decision-making at interim analysis will
compare the Dunnett-corrected p values to stage 1
FWER of 0.2. The first of the three-part criteria for
dropping trial arms will then be considered after exam-
ining final p values at the end of the first stage (interim
analysis). Although sample size will be re-calculated at
the end of stage 1, the total number of clinic days per
arm is still presumed to be small for stage 2. Since the
two stages are assumed to be independent, cluster-level
summaries approach analogous to stage 1 analysis will
also be followed in stage 2 comparing intervention arms
that proceed to stage 2 with the SOC arm. A detailed
analysis plan will be developed to guide analysis of the
trial.
Adaptations at interim analysis (end of stage 1)
Interim analysis at the end of stage 1 will assess whether
any of the five intervention arms should be dropped as
recommended by an independent Data Monitoring and
Safety Board (DSMB) based on a three-part criteria.
First, an arm whose statistical comparison to the SOC
arm yields a p value > 0.2 will be considered for dropping
for futility. Second, any intervention arm with a high in-
cidence of SAEs, i.e. grades 3, 4 or 5 (Table 3) compared
to SOC will be considered for dropping. It is at the dis-
cretion of the DSMB to decide, based on absolute num-
ber of SAEs in each intervention trial arm, whether they
are high or not. Such an observation and recommenda-
tion will then be shared with the investigators who will
make the final decision. Thirdly, an arm may be main-
tained after taking into account the costs associated with
providing the service in light of the p value from statis-
tical analysis. For this cost analysis, we will provide the
DSMB estimates of the incremental cost per male part-
ner tested, and incremental cost per HIV-positive male
identified through the intervention arms in comparison
to the SOC arm. The investigators will access the first-
stage data only after the last follow-up visit for partici-
pants has occurred in order to perform interim analysis.
The CRT extension to the Consolidated Standards of
Reporting Trials (CONSORT) [37] will be followed when
reporting the data.
Discussion
This is the first study that we are aware of that will use
adaptive trial methodology in the context of randomising
clusters rather than individuals. In this paper, we describe
the methodological approaches to developing an adaptive
CRT, to provide timely and cost-efficient understanding of
optimal strategies to improve uptake of HIV testing and
linkage into HIV care and prevention among male part-
ners of pregnant women in a high HIV-prevalent setting.
The methodology and lessons learned here will be import-
ant as proof of concept of how to design and conduct
similar studies in the future. Being a phase II trial means
that fewer resources can be allocated to a “learning” phase
of a major phase III trial to narrow down to interventions
that hold true rather than assumed potential effectiveness.
As a multi-arm trial it allows the investigation of interven-
tions that can act on their own, such as providing self-test
kits only, or in combination, where an incentive or a
reminder is given. This approach, which is one of the key
strengths of adaptive trials, allows generation of clear evi-
dence relating to specific intervention components that
are effective when compared to the SOC.
The 2020 UNAIDS targets set in 2014 aim to diagnose
90% of people living with HIV and to start 90% of those
diagnosed on ART, leading to virus suppression in 90% of
those on ART [5]. While HIVST has been shown to
increase uptake of HIV testing to within the first 90%, very
limited evidence exists on effective interventions for im-
proving linkage into care, the second 90%. In a recent trial
in rural South Africa and Uganda, having a lay counsellor
visit newly diagnosed individuals had minimal impact on
linkage (risk ratio of 1.04) [38]. A combination strategy of
conducting point-of-care CD4 at the time; accelerated
ART initiation for adults with CD4 < 350 cells/uL; mobile
phone appointment reminders; health educational pack-
ages; and non-cash financial incentives improved from
83% in the SOC arm to 92% in CRT in Swaziland [39].
However, the authors acknowledged that the multiplicity
of interventions offered in the trial obscure the isolation
of successful intervention components. Therefore, though
small, this trial will potentially present good evidence on
the type of effective interventions for improving linkage to
HIV care or prevention, and also the right dose for finan-
cial incentives that may be effective.
The trial results will also have important policy impli-
cations on how to implement HIVST targeting male
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partners of pregnant women who are accessing ANC for
the first time while paying particular attention to safety
concerns. In a recent cohort study where HIV-negative
pregnant women collected three oral self-test kits in
Kenya 51% reported that their male partners had self-
tested with none of the women reporting any SAEs [40].
Unlike in the Kenya study, where only HIV-negative
pregnant women were eligible, this trial will recruit
pregnant women, regardless of HIV status, who are at-
tending their first ANC. The group of women recruited
here receive the offer of an HIV test routinely making
this trial design readily scalable. Measuring actual HIV
testing is extremely difficult with HIVST as by definition
disclosure depends on the individual. Our HIV testing
outcome will be measured objectively through observed
returned used/unused self-test kits by the man and also
proxy reporting by the woman which minimises infor-
mation bias.
A major anticipated constraint is potential for SAEs
resulting mainly from intimate partner violence (IPV) to
women, although evidence from studies using other
populations and other HTS models suggests that this ap-
proach is unlikely to increase this problem [6]. A recent
large HIV self-testing study in Malawi found no increase
in IPV, despite an active community liaison system
among 27,000 self-testing participants [20]. We will
carefully monitor IPV, and have deliberately listed this as
a secondary (safety) outcome. Although it will not be
possible for participants and recruiting staff to predict
the next-day recruiting arm, the knowledge of FI arms
may result in altered decision-making about health care
seeking. For example, a woman may choose to postpone
her ANC attendance in the hope of being recruited in a
FI arm, or indeed want to switch between arms.
There is potential for contamination if women in the
intervention arms share their self-test kits with women
in the SOC arm. In order to minimise this problem, we
will ask women and their male partners in the interven-
tion arms to bring used or unused self-test kits at
follow-up and when they link into the MFC, respectively.
We will also attempt to measure the magnitude of this
problem by asking all women and male partners who
link into the MFC in the SOC arm if they received self-
test kits. There is potential bias in the estimation of the
treatment effect and confidence intervals due to interim
selection process of potential effective interventions
which we will not explore.
Trial status
At the time of submission on 9 November 2016, 32 of
36 clusters (total of 800 participants recruited) were cov-
ered for the first of the two trial stages. Interim analysis
is planned for 20 January 2017. The second stage is
planned to run for 4 months; we will compute the re-
quired sample size for the second stage at interim ana-
lysis to achieve the specified 80% power.
Additional file
Additional file 1: SPIRIT Checklist. (DOC 151 kb)
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Table 3 Adverse event grading
Grade 1
(Mild)
Grade 2
(Moderate)
Grade 3
(Severe)
(within 30 days)
Grade 4
(Potentially life-threatening)
(within 30 days)
1. Verbal, emotional or
psychological intimate-
partner violence (IPV)
2. Denying access to
household resources
3. Being ignored
4. Being controlled (e.g. not
allowed to leave house)
1. Coercion to self-test.
2. Coercion to disclose a
self-test result
3. IPV that includes pushing, or
slapping with an open hand
that does not result in pain, or
visible marks >24 h
4. Severe or prolonged
psychological or emotional
IPV leading to disruption of
daily activities
5. Psychologically coercive sex
1. IPV that leads to pain, bruising
or marks >24 hr
2. Threat of life-threatening
violence (e.g. statement of
intent to kill, mock
strangulation, threatened with
a knife or gun)
3. Physically coercive sex
4. Reports fearing for her life
5. Marriage break-up
1. IPV leading to hospitalisation
or death
2. Suicide or attempted suicide
3. Attack using potentially lethal force
(e.g. knife, gun, hammer,
kicks to the head)
Grade 1 indicates a mild event
Grade 2 indicates a moderate event
Grade 3 indicates a severe event
Grade 4 indicates a potentially life-threatening event
Grade 5 indicates death: not indicated on the table
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